Stock listing
Wpd Pharmaceuticals Inc
Selected listing: WBIO · CSE · CAD · CA
Wpd Pharmaceuticals Inc (CSE:WBIO), Health Technology. Latest release Dec 5, 2024: WPD Pharmaceuticals : PROPOSED SHARE CONSOLIDATION OF WPD’S COMMON SHARES.
- Ticker
- CSE:WBIO
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- CSE
- Currency
- CAD
About Wpd Pharmaceuticals Inc
The company focuses on developing innovative pharmaceutical solutions. Wpd Pharmaceuticals aims to address unmet medical needs through its research and development efforts in the healthcare sector.
Latest news from Wpd Pharmaceuticals Inc
WPD Pharmaceuticals : PROPOSED SHARE CONSOLIDATION OF WPD’S COMMON SHARES
December 5, 2024
WPD Pharmaceuticals : ANNOUNCES SETTLEMENT OF DEBT FOR COMMON SHARES
July 25, 2024
WPD Pharmaceuticals : REINSTATEMENT OF TRADING OF WPD'S COMMON SHARES AND ANNUAL GENERAL MEETING
May 30, 2024
WPD Pharmaceuticals : Receives Full Revocation of Cease Trade Order
May 16, 2024
WPD Pharmaceuticals : Announces Filing of Annual Financial Statements and Provides Corporate Update
May 10, 2024
Research Wpd Pharmaceuticals Inc
Wpd Pharmaceuticals Inc company profile
View the public company page for Wpd Pharmaceuticals Inc on 6ix.
Wpd Pharmaceuticals Inc news
Read company news and market updates connected to Wpd Pharmaceuticals Inc.
Wpd Pharmaceuticals Inc investor events
Find investor webinars, events, and replay context for Wpd Pharmaceuticals Inc.
Alternate listings
8SV:MUN
DE · EUR
Alternate listing for Wpd Pharmaceuticals Inc; the primary context on this page is WBIO:CSE.
8SV:HAM
DE · EUR
Alternate listing for Wpd Pharmaceuticals Inc; the primary context on this page is WBIO:CSE.
A40XCT:LS
DE · EUR
Alternate listing for Wpd Pharmaceuticals Inc; the primary context on this page is WBIO:CSE.
A40XCT:LSX
DE · EUR
Alternate listing for Wpd Pharmaceuticals Inc; the primary context on this page is WBIO:CSE.
WBIO:NEO
CA · CAD
Alternate listing for Wpd Pharmaceuticals Inc; the primary context on this page is WBIO:CSE.